FGEN Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-03-23 | Wettig Thane | officer: Chief Commercial Officer | 110,653 | S-Sale | D | 905 | 18.71 | 16,932.55 |
| 2023-03-10 | Conterno Enrique A | director, officer: Chief Executive Officer | 384,868 | S-Sale | D | 19,489 | 20.20 | 393,625.18 |
| 2023-03-10 | Chung Christine | officer: SVP, China Operations | 259,050 | S-Sale | D | 2,914 | 20.20 | 58,854.93 |
| 2023-03-10 | Chung Christine | officer: SVP, China Operations | 261,964 | S-Sale | D | 4,692 | 20.20 | 94,765.73 |
| 2023-03-10 | Conterno Enrique A | director, officer: Chief Executive Officer | 404,357 | S-Sale | D | 12,103 | 20.20 | 244,447.92 |
| 2023-03-10 | Wettig Thane | officer: Chief Commercial Officer | 111,558 | S-Sale | D | 4,731 | 20.20 | 95,553.43 |
| 2023-03-10 | Wettig Thane | officer: Chief Commercial Officer | 116,289 | S-Sale | D | 2,938 | 20.20 | 59,339.67 |
| 2023-03-10 | Graham Juan | officer: Chief Financial Officer | 72,868 | S-Sale | D | 2,344 | 20.20 | 47,342.47 |
| 2023-03-10 | Graham Juan | officer: Chief Financial Officer | 75,212 | S-Sale | D | 1,456 | 20.20 | 29,407.27 |
| 2023-03-10 | Graham Juan | officer: Chief Financial Officer | 76,668 | S-Sale | D | 1,112 | 20.20 | 22,459.40 |
| 2023-03-10 | Eisner Mark | officer: Chief Medical Officer | 175,176 | S-Sale | D | 6,255 | 20.20 | 126,334.11 |
| 2023-03-10 | Eisner Mark | officer: Chief Medical Officer | 181,431 | S-Sale | D | 3,885 | 20.20 | 78,466.51 |
| 2023-03-08 | Chung Christine | officer: SVP, China Operations | 266,656 | A-Award | A | 9,338 | 0.00 | 0.00 |
| 2023-03-08 | Chung Christine | officer: SVP, China Operations | 257,318 | A-Award | A | 5,799 | 0.00 | 0.00 |
| 2023-03-08 | Chung Christine | officer: SVP, China Operations | 251,519 | S-Sale | D | 8,354 | 21.16 | 176,736.39 |
| 2023-03-08 | Conterno Enrique A | director, officer: Chief Executive Officer | 416,460 | A-Award | A | 37,229 | 0.00 | 0.00 |
| 2023-03-08 | Conterno Enrique A | director, officer: Chief Executive Officer | 379,231 | A-Award | A | 23,120 | 0.00 | 0.00 |
| 2023-03-08 | Conterno Enrique A | director, officer: Chief Executive Officer | 356,111 | S-Sale | D | 24,672 | 21.16 | 521,958.36 |
| 2023-03-08 | Wettig Thane | officer: Chief Commercial Officer | 119,227 | A-Award | A | 9,338 | 0.00 | 0.00 |
| 2023-03-08 | Wettig Thane | officer: Chief Commercial Officer | 109,889 | A-Award | A | 5,799 | 0.00 | 0.00 |
| 2023-03-08 | Wettig Thane | officer: Chief Commercial Officer | 104,090 | S-Sale | D | 6,265 | 21.16 | 132,541.71 |
| 2023-03-08 | Graham Juan | officer: Chief Financial Officer | 77,780 | A-Award | A | 4,668 | 0.00 | 0.00 |
| 2023-03-08 | Graham Juan | officer: Chief Financial Officer | 73,112 | A-Award | A | 2,899 | 0.00 | 0.00 |
| 2023-03-08 | Graham Juan | officer: Chief Financial Officer | 70,213 | S-Sale | D | 2,749 | 21.16 | 58,157.57 |
| 2023-03-08 | Eisner Mark | officer: Chief Medical Officer | 185,316 | A-Award | A | 12,451 | 0.00 | 0.00 |
| 2023-03-08 | Eisner Mark | officer: Chief Medical Officer | 172,865 | A-Award | A | 7,732 | 0.00 | 0.00 |
| 2023-03-08 | Eisner Mark | officer: Chief Medical Officer | 165,133 | S-Sale | D | 7,363 | 21.16 | 155,770.89 |
| 2023-03-02 | Eisner Mark | officer: Chief Medical Officer | 172,496 | S-Sale | D | 1,187 | 21.87 | 25,959.69 |
| 2023-02-21 | Graham Juan | officer: Chief Financial Officer | 42,000 | A-Award | A | 42,000 | 22.60 | 949,200.00 |
| 2023-02-21 | Graham Juan | officer: Chief Financial Officer | 72,962 | A-Award | A | 25,000 | 0.00 | 0.00 |
| 2023-02-21 | Wettig Thane | officer: Chief Commercial Officer | 42,000 | A-Award | A | 42,000 | 22.60 | 949,200.00 |
| 2023-02-21 | Wettig Thane | officer: Chief Commercial Officer | 110,355 | A-Award | A | 25,000 | 0.00 | 0.00 |
| 2023-02-21 | Eisner Mark | officer: Chief Medical Officer | 55,000 | A-Award | A | 55,000 | 22.60 | 1,243,000.00 |
| 2023-02-21 | Eisner Mark | officer: Chief Medical Officer | 173,683 | A-Award | A | 32,500 | 0.00 | 0.00 |
| 2023-02-21 | Chung Christine | officer: SVP, China Operations | 42,000 | A-Award | A | 42,000 | 22.60 | 949,200.00 |
| 2023-02-21 | Chung Christine | officer: SVP, China Operations | 259,873 | A-Award | A | 25,000 | 0.00 | 0.00 |
| 2023-02-21 | Conterno Enrique A | director, officer: Chief Executive Officer | 143,100 | A-Award | A | 143,100 | 22.60 | 3,234,060.00 |
| 2023-02-21 | Conterno Enrique A | director, officer: Chief Executive Officer | 380,783 | A-Award | A | 85,300 | 0.00 | 0.00 |
| 2023-01-06 | Conterno Enrique A | director, officer: Chief Executive Officer | 295,483 | S-Sale | D | 1,538 | 19.95 | 30,683.10 |
| 2022-12-23 | Wettig Thane | officer: Chief Commercial Officer | 89,163 | S-Sale | D | 734 | 15.80 | 11,597.20 |
| 2022-12-12 | Graham Juan | officer: Chief Financial Officer | 47,962 | S-Sale | D | 1,407 | 14.50 | 20,401.50 |
| 2022-12-12 | Graham Juan | officer: Chief Financial Officer | 53,703 | S-Sale | D | 1,407 | 14.50 | 20,401.50 |
| 2022-12-09 | Graham Juan | officer: Chief Financial Officer | 49,369 | S-Sale | D | 781 | 14.89 | 11,629.09 |
| 2022-12-09 | Graham Juan | officer: Chief Financial Officer | 55,110 | S-Sale | D | 781 | 14.90 | 11,636.90 |
| 2022-12-08 | Chung Christine | officer: SVP, China Operations | 234,873 | S-Sale | D | 2,595 | 15.79 | 40,975.05 |
| 2022-12-08 | Graham Juan | officer: Chief Financial Officer | 50,150 | S-Sale | D | 478 | 15.47 | 7,394.66 |
| 2022-12-08 | Graham Juan | officer: Chief Financial Officer | 50,628 | S-Sale | D | 5,263 | 14.84 | 78,102.92 |
| 2022-12-08 | Conterno Enrique A | director, officer: Chief Executive Officer | 297,020 | S-Sale | D | 2,543 | 15.79 | 40,153.97 |
| 2022-12-08 | Wettig Thane | officer: Chief Commercial Officer | 89,897 | S-Sale | D | 382 | 15.79 | 6,031.78 |
| 2022-12-08 | Chung Christine | officer: SVP, China Operations | 237,705 | S-Sale | D | 1,096 | 15.79 | 17,305.84 |
| 2022-12-01 | Eisner Mark | officer: Chief Medical Officer | 141,183 | F-InKind | D | 1,084 | 15.04 | 16,303.36 |
| 2022-10-06 | Conterno Enrique A | director, officer: Chief Executive Officer | 299,563 | F-InKind | D | 1,296 | 14.26 | 18,480.96 |
| 2022-09-30 | Chung Christine | officer: SVP, China Operations | 238,801 | F-InKind | D | 4,683 | 13.01 | 60,925.83 |
| 2022-09-30 | Eisner Mark | officer: Chief Medical Officer | 142,267 | F-InKind | D | 6,777 | 13.01 | 88,168.77 |
| 2022-09-22 | Wettig Thane | officer: Chief Commercial Officer | 90,279 | F-InKind | D | 655 | 12.26 | 8,030.30 |
| 2022-09-07 | Graham Juan | officer: Chief Financial Officer | 55,891 | F-InKind | D | 3,009 | 12.62 | 37,973.58 |
| 2022-09-06 | Chung Christine | officer: SVP, China Operations | 242,151 | F-InKind | D | 1,851 | 12.26 | 22,693.26 |
| 2022-09-06 | Chung Christine | officer: SVP, China Operations | 243,484 | F-InKind | D | 518 | 12.26 | 6,350.68 |
| 2022-09-06 | Conterno Enrique A | director, officer: Chief Executive Officer | 300,859 | F-InKind | D | 1,772 | 12.26 | 21,724.72 |
| 2022-09-06 | Wettig Thane | officer: Chief Commercial Officer | 90,934 | F-InKind | D | 360 | 12.26 | 4,413.60 |
| 2022-09-01 | Eisner Mark | officer: Chief Medical Officer | 149,044 | F-InKind | D | 756 | 13.09 | 9,896.04 |
| 2022-08-22 | Wettig Thane | officer: Chief Commercial Officer | 85,355 | G-Gift | D | 1,820 | 0.00 | 0.00 |
| 2022-07-06 | Conterno Enrique A | director, officer: Chief Executive Officer | 302,631 | F-InKind | D | 1,296 | 12.40 | 16,070.40 |
| 2022-06-22 | Wettig Thane | officer: Chief Commercial Officer | 91,294 | F-InKind | D | 655 | 11.42 | 7,480.10 |
| 2022-06-16 | Henderson Jeffrey William | director | 25,684 | A-Award | A | 25,684 | 9.00 | 231,156.00 |
| 2022-06-16 | Henderson Jeffrey William | director | 33,577 | A-Award | A | 15,777 | 0.00 | 0.00 |
| 2022-06-16 | Ho Maykin | director | 25,684 | A-Award | A | 25,684 | 9.00 | 231,156.00 |
| 2022-06-16 | Ho Maykin | director | 31,732 | A-Award | A | 15,777 | 0.00 | 0.00 |
| 2022-06-16 | EDWARDS JEFFREY L | director | 25,684 | A-Award | A | 25,684 | 9.00 | 231,156.00 |
| 2022-06-16 | EDWARDS JEFFREY L | director | 33,577 | A-Award | A | 15,777 | 0.00 | 0.00 |
| 2022-06-16 | Cravatt Benjamin | director | 25,684 | A-Award | A | 25,684 | 9.00 | 231,156.00 |
| 2022-06-16 | Cravatt Benjamin | director | 24,391 | A-Award | A | 15,777 | 0.00 | 0.00 |
| 2022-06-16 | Brennan Aoife | director | 25,684 | A-Award | A | 25,684 | 9.00 | 231,156.00 |
| 2022-06-16 | Brennan Aoife | director | 24,391 | A-Award | A | 15,777 | 0.00 | 0.00 |
| 2022-06-16 | Lema Gerald | director | 25,684 | A-Award | A | 25,684 | 9.00 | 231,156.00 |
| 2022-06-16 | Lema Gerald | director | 20,477 | A-Award | A | 15,777 | 0.00 | 0.00 |
| 2022-06-16 | Blaug Suzanne | director | 25,684 | A-Award | A | 25,684 | 9.00 | 231,156.00 |
| 2022-06-16 | Blaug Suzanne | director | 29,825 | A-Award | A | 15,777 | 0.00 | 0.00 |
| 2022-06-16 | Schoeneck James A | director | 25,684 | A-Award | A | 25,684 | 9.00 | 231,156.00 |
| 2022-06-16 | Schoeneck James A | director | 20,477 | A-Award | A | 15,777 | 0.00 | 0.00 |
| 2022-06-06 | Chung Christine | officer: SVP, China Operations | 244,002 | F-InKind | D | 1,850 | 9.50 | 17,575.00 |
| 2022-06-06 | Wettig Thane | officer: Chief Commercial Officer | 89,961 | F-InKind | D | 360 | 9.50 | 3,420.00 |
| 2022-06-06 | Conterno Enrique A | director, officer: Chief Executive Officer | 301,940 | F-InKind | D | 1,772 | 9.50 | 16,834.00 |
| 2022-06-01 | Eisner Mark | officer: Chief Medical Officer | 149,800 | F-InKind | D | 1,141 | 9.61 | 10,965.01 |
| 2022-05-25 | Wettig Thane | officer: Chief Commercial Officer | 87,175 | G-Gift | D | 1,988 | 0.00 | 0.00 |
| 2022-04-07 | Conterno Enrique A | director, officer: Chief Executive Officer | 303,712 | F-InKind | D | 1,311 | 12.73 | 16,689.03 |
| 2022-03-31 | Eisner Mark | officer: Chief Medical Officer | 150,941 | F-InKind | D | 6,442 | 12.02 | 77,432.84 |
| 2022-03-31 | Chung Christine | officer: SVP, China Operations | 245,852 | F-InKind | D | 4,682 | 12.02 | 56,277.64 |
| 2022-03-22 | Wettig Thane | officer: Chief Commercial Officer | 90,321 | F-InKind | D | 655 | 13.31 | 8,718.05 |
| 2022-03-07 | Wettig Thane | officer: Chief Commercial Officer | 90,976 | F-InKind | D | 1,706 | 12.69 | 21,649.14 |
| 2022-03-07 | Conterno Enrique A | director, officer: Chief Executive Officer | 305,023 | F-InKind | D | 7,081 | 12.69 | 89,857.89 |
| 2022-03-07 | Chung Christine | officer: SVP, China Operations | 250,534 | F-InKind | D | 3,905 | 12.69 | 49,554.45 |
| 2022-03-01 | Eisner Mark | officer: Chief Medical Officer | 157,383 | F-InKind | D | 756 | 13.62 | 10,296.72 |
| 2022-02-14 | Graham Juan | officer: Chief Financial Officer | 37,500 | A-Award | A | 37,500 | 15.60 | 585,000.00 |
| 2022-02-14 | Graham Juan | officer: Chief Financial Officer | 58,900 | A-Award | A | 22,500 | 0.00 | 0.00 |
| 2022-02-14 | Wettig Thane | officer: Chief Commercial Officer | 75,000 | A-Award | A | 75,000 | 15.60 | 1,170,000.00 |
| 2022-02-14 | Wettig Thane | officer: Chief Commercial Officer | 92,682 | A-Award | A | 45,000 | 0.00 | 0.00 |
| 2022-02-14 | Eisner Mark | officer: Chief Medical Officer | 100,000 | A-Award | A | 100,000 | 15.60 | 1,560,000.00 |
| 2022-02-14 | Eisner Mark | officer: Chief Medical Officer | 158,139 | A-Award | A | 60,000 | 0.00 | 0.00 |
| 2022-02-14 | Conterno Enrique A | director, officer: Chief Executive Officer | 298,000 | A-Award | A | 298,000 | 15.60 | 4,648,800.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.